抗肥胖藥物市場、機會、成長動力、產業趨勢分析與預測，2024-2032

在藥物開發的不斷推出和創新的帶動下，抗肥胖藥物市場規模預計從 2024 年到 2032 年將以 27% 的複合年成長率擴大。

新的抗肥胖藥物正在推出，以提高控制體重的功效和安全性。對肥胖生物學機制的持續研究和進展正在推動更具針對性和更有效的抗肥胖藥物的開發。此外，基因組學和生物技術的創新正在促進針對肥胖患者的不同需求開發精準療法。例如，2024 年 1 月，抗肥胖藥物 Zepbound 的製造商禮來公司 (Eli Lilly) 推出了直接面向患者的入口網站 LillyDirect。此措施旨在提高抗肥胖藥物的可近性，同時簡化治療過程並提高患者的參與度。

整個市場分為產品、行動途徑、配銷通路和區域。

從產品來看，由於體重管理解決方案的需求不斷成長，預計 2024 年至 2032 年，非處方藥領域的抗肥胖藥物市場價值將以顯著的複合年成長率成長。 OTC（非處方藥）選項使個人無需處方即可更輕鬆地對抗肥胖。這些非處方抗肥胖藥物還具有有效的成分和更安全的特性，支持減肥努力。

到 2032 年，抗肥胖藥物市場的電子商務配銷通路領域將經歷大幅成長。由於便利性和更廣泛的選擇，消費者開始轉向電子商務平台購買抗肥胖藥物。線上零售商也在使其產品多樣化，推出各種配方和品牌，以滿足追求體重管理解決方案的人們的需求。

亞太地區抗肥胖藥物市場預計到 2032 年將顯著成長，這主要是由於醫療保健支出不斷增加。醫療保健投資的增加正在將更多資源投入到抗肥胖治療的開發和銷售中。因此，隨著醫療保健支出持續增加，將促進抗肥胖藥物的擴展和可近性。這確保了更廣泛的人群能夠獲得有效的肥胖管理解決方案，最終提高該地區的整體健康水平。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 肥胖相關疾病的盛行率不斷增加
    • 政府法規和指南
    • 技術進步的增加
  • 產業陷阱與挑戰
    • 副作用和不良反應
    • 抗肥胖藥物成本高
• 成長潛力分析
• 監管環境
• 技術景觀
  • 核心技術
  • 鄰近技術
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 處方藥
• 非處方藥

第 6 章：市場估計與預測：按行動路徑，2021 - 2032

• 主要趨勢
• 周邊作用藥物
• 中樞作用藥物

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 藥妝店
• 電子商務

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Arena Pharmaceuticals, Inc.
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Currax Pharmaceuticals LLC
• Eli Lily and Co
• F. Hoffmann-La Roche Ltd.
• Gelesis
• GlaxoSmithKline plc
• Merck and Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Orexigen Therapeutics, Inc.
• Pfizer Inc.
• Rhythm Pharmaceuticals, Inc.
• Vivus, Inc.

Anti-Obesity Drugs Market size is projected to expand at a 27% CAGR from 2024 to 2032, led by increasing launches and innovations in drug development.

New anti-obesity medications are being introduced to offer improved efficacy and safety profiles for managing weight. Ongoing research and advancements in understanding the biological mechanisms of obesity are driving the development of more targeted and effective anti-obesity drugs. Furthermore, innovations in genomics and biotechnology are facilitating the creation of precise therapies tailored to the diverse needs of individuals grappling with obesity. For instance, in January 2024, Eli Lilly, the maker of the anti-obesity drug Zepbound, launched LillyDirect, a direct-to-patient portal. This initiative aimed to enhance access to anti-obesity medications while simplifying the treatment process and boosting patient engagement.

The overall market is segregated into product, action pathway, distribution channel, and region.

Based on product, the anti-obesity drugs market value from the OTC drugs segment is estimated to rise at a significant CAGR from 2024 to 2032, attributed to the growing demand for weight management solutions. OTC (over-the-counter) options are granting individuals easier access to combat obesity without needing a prescription. These OTC anti-obesity drugs also boast effective ingredients and safer profiles, bolstering weight loss endeavors.

The e-commerce distribution channel segment in the anti-obesity drugs market is set to experience substantial growth until 2032. This is driven by the increasing demand for accessible treatments. Consumers are turning to e-commerce platforms for their anti-obesity medications, drawn by convenience and wider selection. Online retailers are also diversifying their offerings, presenting various formulations and brands to cater to those pursuing weight management solutions.

Asia Pacific anti-obesity drugs market is poised for notable growth by 2032, largely due to escalating healthcare expenditures. Heightened investments in healthcare are channeling more resources into the development and distribution of anti-obesity treatments. Consequently, as healthcare expenditures continue to rise, they will bolster the expansion and accessibility of anti-obesity drugs. This that ensures a broader segment of the population can access effective solutions for obesity management, ultimately enhancing overall health in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of obesity-related conditions
    • 3.2.1.2 Government regulations and guidelines
    • 3.2.1.3 Increase in technological advancements
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects and adverse reactions
    • 3.2.2.2 High cost of anti-obesity drugs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Prescription drugs
• 5.3 OTC drugs

Chapter 6 Market Estimates and Forecast, By Action Pathway, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Peripherally acting drugs
• 6.3 Centrally acting drugs

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Drug stores
• 7.5 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Arena Pharmaceuticals, Inc.
• 9.2 AstraZeneca PLC
• 9.3 Boehringer Ingelheim International GmbH
• 9.4 Currax Pharmaceuticals LLC
• 9.5 Eli Lily and Co
• 9.6 F. Hoffmann-La Roche Ltd.
• 9.7 Gelesis
• 9.8 GlaxoSmithKline plc
• 9.9 Merck and Co., Inc.
• 9.10 Novartis AG
• 9.11 Novo Nordisk A/S
• 9.12 Orexigen Therapeutics, Inc.
• 9.13 Pfizer Inc.
• 9.14 Rhythm Pharmaceuticals, Inc.
• 9.15 Vivus, Inc.